Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients
AYS Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, G-S Ngian, J Roddy, PJ Roberts-Thomson, JG Walker
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | TAYLOR & FRANCIS LTD | Published : 2021
Objective: We undertook a comprehensive cross-sectional analysis of a multicentred Australian cohort of systemic sclerosis (SSc) patients to evaluate the associations of anti-Ro52/TRIM21 with SSc pulmonary involvement.Method: The study included 596 patients from the Australian Scleroderma Cohort Study database whose anti-Ro52/TRIM21 status was known. Anti-Ro52/TRIM21 was measured via line immunoassay. Data on demographic variables, autoantibody profiles, presence of interstitial lung disease (ILD), presence of pulmonary arterial hypertension (PAH), oxygen saturation, Six-Minute Walk Test distance, Borg dyspnoea score, and lung function tests were extracted. SPSS software was used to examine ..View full abstract
Awarded by NHMRC Emerging Leadership Investigator Grant
The Australian Scleroderma Cohort Study (ASCS) is supported by Actelion Pharmaceuticals Australia, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia, the Scleroderma Clinical Trials Consortium (SCTC), St Vincent's Hospital Research Endowment Fund, the Australian Rheumatology Association, philanthropic donations, GlaxoSmithKline, Roche, Pfizer, Bayer, CSL Biotherapies, and Bristol-Myers Squibb. MN holds an NHMRC Emerging Leadership Investigator Grant (GNT1176538).